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Abstract  44 
 45 
Background: Indoleamine 2,3-dioxygenase (IDO), the first step in the kynurenine 46 
pathway (KP), is upregulated in some cancers and represents an attractive therapeutic 47 
target given its role in tumour immune evasion. However, the recent failure of  an IDO 48 
inhibitor in a late phase trial raises questions about this strategy.  49 
Methods: Matched renal cell carcinoma (RCC) and normal kidney tissues were subject 50 
to proteomic profiling. Tissue immunohistochemistry and gene expression data were used 51 
to validate findings. Phenotypic effects of loss/gain of expression were examined in vitro.  52 
Results: Quinolate phosphoribosyltransferase (QPRT), the final and rate-limiting enzyme 53 
in the KP, was identified as being down-regulated in RCC. Loss of QPRT expression led 54 
to increased potential for anchorage-independent growth. Gene expression, mass 55 
spectrometry (clear cell and chromophobe RCC) and tissue immunohistochemistry (clear 56 
cell, papillary and chromophobe), confirmed loss or decreased expression of QPRT, and 57 
showed down-regulation of other KP enzymes including kynurenine 3-monoxygenase 58 
(KMO) and 3-hydroxyanthranilate-3,4-dioxygenase (HAAO), with a concomitant 59 
maintenance or up-regulation of nicotinamide phosphoribosyltransferase (NAMPT), the 60 
key enzyme in the NAD+ salvage pathway.  61 
Conclusions: Widespread dysregulation of the KP is common in RCC and is likely to 62 
contribute to tumour immune evasion, carrying implications for effective therapeutic 63 














Renal cancer is one of the ten most common adult cancers, accounting for over 100,000 75 
deaths worldwide each year.1 It is also a cancer with one of the highest projected 76 
increases in incidence over the next two decades.2 Almost 90% of these cancers arise 77 
within the renal parenchyma and are termed renal cell carcinomas (RCCs). The most 78 
common (75%) histological subtype is clear cell RCC (conventional) (ccRCC), which are 79 
characterised by loss of the VHL tumour suppressor gene, followed by papillary (10-15%) 80 
and chromophobe (5%) RCC. Each is considered to arise from distinct parts of the human 81 
nephron, are genetically distinct3 and vary considerably in their clinical behaviour. 82 
Treatment options for patients with RCC have burgeoned in recent years but, despite this, 83 
it is a cancer that remains incurable for most patients with advanced disease. As in a 84 
number of other tumour types, immunotherapy, in the form of checkpoint inhibitors (CPI), 85 
has come to the forefront of patient treatment, both in the first- and second-line settings. 86 
However, whilst some patients are observed to have deep and durable responses to these 87 
agents, many patients fail to respond.4 It appears, therefore, that alone, CPI are not always 88 
sufficient to overcome immune evasion and immune tolerance by tumours. Hence, 89 
increasing attention is being focused on combining these drugs with other immune-90 
modifying targeted agents.5 91 
Alterations in cellular metabolism are a hallmark of cancer,6 most notably perhaps the  92 
‘Warburg effect’, that describes the increased rate of glycolysis with reduced oxidative 93 
phosphorylation characteristic of tumours.7 We were amongst the first to demonstrate this 94 
comprehensively in renal cancers, using a proteomic approach, showing an up-regulation 95 
in the majority of proteins in the glycolytic pathway and a parallel downregulation of 96 
mitochondrial enzymes in comparison to normal renal tissues,8 highlighting novel 97 
opportunities for therapeutic targeting.9   98 
More recently, alteration in the metabolism of the essential amino acid tryptophan in 99 




which tumours may escape immune control and promote disease progression. The 101 
enzymes indoleamine 2,3-dioxygenase (IDO1, IDO2) and tryptophan 2,3-dioxygenase 102 
(TDO) initiate the first steps in the kynurenine pathway, converting tryptophan to 103 
kynurenine, with the TDO-dependent pathway in the liver normally accounting for the 104 
majority of tryptophan metabolism and IDO-mediated metabolism predominantly 105 
occurring secondary to inflammation and cytokine-induced upregulation.10 In normal 106 
physiology, IDO plays an important role in tolerance to non-self antigens, for example fetal 107 
antigens, where such immune non-responsiveness may be important.11,12 Up-regulation 108 
of IDO leads to tryptophan depletion and kynurenine accumulation, which appear to work 109 
in concert to mediate immunosuppression, via T-cell anergy and apoptosis and 110 
suppressed T-cell differentiation.13 The harnessing of this phenomenon by tumours has 111 
led to the development of inhibitors of IDO1 that have progressed to clinical trials in 112 
combination with CPI. Despite much promise, initial results have, however, been 113 
disappointing and the future of these agents currently remains uncertain.14,15 This may be 114 
because of patient selection and lack of suitable profiling of immuno-regulating 115 
metabolism, emphasising the need for a deeper understanding of these pathways. 116 
Here, using a proteomic-based approach, we show that the kynurenine pathway is more 117 
broadly disrupted than has been previously considered, extending beyond IDO1, that this 118 
is a common event in RCC and is not just restricted to the clear cell histological subtype, 119 
and suggests possible redundancy in the pathway within the tumour setting.  Our findings 120 
are of significance in terms of highlighting various aspects of this pathway for potential 121 
therapeutic targeting, patient stratification and  may have implications for other cancers. 122 
  123 
  124 
 125 




Materials and Methods 127 
Reagents 128 
Reagents were purchased as follows: general chemicals (Sigma, Poole, UK and VWR, 129 
Poole, UK), goat serum and human serum albumin (HSA), mouse monoclonal anti-β-actin 130 
antibody clone AC15 (Sigma), Hybond™C super NC membrane, Pharmalyte pH 3–10, 131 
IPG strips, Dry strip cover fluid, bromophenol blue and PlusOne Silver Stain (GE 132 
Healthcare,Little Chalfont, UK), CHAPS (Calbiochem, San Diego, USA), LMP agarose, 133 
MEM-Alpha medium, L-glutamine, trypsin with EDTA, G418, HBSS and Antibody Diluent 134 
(Invitrogen Life Technologies, Paisley, UK), foetal calf serum (FCS; Harlan-Seralab , 135 
Sussex, UK); PBS (Oxoid, Basingstoke, UK), acrylamide (National Diagnostics, Hull, UK),  136 
OWL Silver Stain (OWL Separation Systems, Portsmouth, USA), trypsin sequencing 137 
grade (Promega, Southampton, UK), ACN (Rathburn, Walkerburn, UK), Complete™ mini 138 
protease inhibitor cocktail tablets (Roche, Lewes, UK), Envision™1 systems (Dako, Ely, 139 
UK),  SuperSignal® West Dura Extended Duration Substrate (Pierce, Tattenhall, UK), 140 
Access Revelation solution (Menarini Diagnostics, Berkshire, UK), Bloxall, Impress Rabbit 141 
HRP!conjugated secondary antibodies, Impact DAB and horse serum (Vector 142 
Laboratories,  Peterborough, UK), BCA protein assay (Thermo Scientific, Warrington, UK) 143 
mouse monoclonal anti-VHL clone Ig32 (BD Biosciences, Wokingham, UK), affinity-144 
purified rabbit antibodies to kynurenine pathway components KMO (cat. nos. HPA056942 145 
and HPA031115), KYNU (cat. no.HPA031686), NAMPT (cat. no. HPA047776) and IDO1 146 
(cat. no. HPA023072) (Atlas Antibodies, Sweden), oligonucleotides (Eurogentec).  147 
 148 
Established cell line VHL transfectants 149 
Cell line pairs generated from the VHL defective human RCC cell lines UMRC2, RCC4 150 
and 786-0 by stable transfection with either empty vector or a wild-type (WT) VHL 151 




full length VHL (786+VHL) or control vector (786+pRC) were obtained as gifts from W.G. 153 
Kaelin 16. Cells were maintained in MEM-α medium supplemented with 10% v/v FCS, 1% 154 
v/v L-glutamine, as previously described.19 All cell lines were screened for mycoplasma 155 
contamination. 156 
 157 
QPRT expression and QPRT knockdown stable transfectants 158 
QPRT gene expression constructs containing empty vector (pFB-HYG) or QPRT (pFB-159 
HYG-QPRT) were created. The QPRT insert was made by PCR of human cDNA (forward 160 
primer: GTCAGTCGACCACCATGGACGCTGAAGGCC and reverse primer 161 
GACTCGAGCTAGTGGATTTTGGGCACTGGAGC) followed by digestion with Sal1 and 162 
Xho1 and ligation into the multiple cloning site of pFB. Correct sequence was confirmed 163 
by sequencing. These constructs were amplified in XL1 Blue competent E. coli 164 
(Stratagene), then introduced into 293-PhoenixA cells using SiPORT transfection agent 165 
(Ambion). Supernatant containing viral particles was harvested on days 3 and 4, and 166 
polybrene added to 8µg/ml. 4ml of medium was used to infect each T75 flask of a VHL-167 
defective 786-0 cell line lacking endogenous VHL followed by selection with hygromycin 168 
(0.5mg/ml), and were designated 786+pFB and 786+QPRT respectively. Cells were 169 
maintained in MEM-α medium supplemented with 10% foetal calf serum (FCS), 1% v/v L-170 
glutamine, G418 (1 mg/ml) and hygromycin selection (0.5mg/ml).  171 
QPRT shRNA constructs containing a non-specific shRNA (pRetroSuper-shRNA-172 
scramble) or shRNA targeting QPRT (pRetroSuper-shRNA-QPRT) were created using 173 
the following oligonucleotides (capitals indicate nucleotides corresponding to QPRT 174 
sequence or control, lower case indicates loop and linker sequences):  175 
shQPRT:  176 
Forward 177 






Scramble:  181 




Oligonucleotide pairs were annealed by heating to 100°C for 2 min and cooling slowly to 186 
room temperature, and ligated into HindIII/BglII digested pRetroSuper-puro (a gift from 187 
Darren Tomlinson). Constructs were amplified in XL1 Blue competent E. coli (Stratagene), 188 
then introduced into 293-PhoenixA cells using SiPORT transfection agent (Ambion). 189 
Supernatant containing viral particles was harvested on days 3 and 4, and polybrene 190 
added to 8µg/ml. 4ml of medium was used to infect each T75 flask of 786+VHL cells, 191 
followed by selection with puromycin (2µg/ml). Cell lines were maintained in MEM-α 192 
medium supplemented with 10% FCS, 1% v/v L-glutamine, G418 (1 mg/ml) and 193 
puromycin (2 µg/ml). 194 
 195 
Two-dimensional gel electrophoresis 196 
For global protein profiling of 786-0 cells +/- VHL, protein extracts (80 µg protein for 197 
analytical gels and 1 mg for preparative gels) were analysed by two-dimensional 198 
polyacrylamide gel electrophoresis (2D-PAGE) over a pH range of 4-7 using a combined 199 
IPGPhor and Multiphor approach.20 Protein samples were loaded onto IPG strips by 200 
overnight in-gel rehydration and focussing carried out for a total of 65kVh. Strips were 201 
equilibrated in running buffer, placed onto polyacrylamide gels (10% resolving gel with 4% 202 
stacking gel), and electrophoresed overnight (12.5°C, 18mA/gel). Gels were stained using 203 




images from triplicate gels were analysed using Melanie 3 software. Preparative gels were 205 
stained with PlusOne™ Silver Stain using a modified staining protocol21 and selected 206 
spots excised and digested with trypsin.22 Peptides were analysed by Nano-LC (Ultimate, 207 
LC Packings (Dionex), Camberley, UK) followed by automated data-dependent MS/MS 208 
using a Q-TOF mass spectrometer (Micromass, Manchester, UK).  Protein identities were 209 
determined by searching the NCBI database using MS-TAG or MS-Pattern 210 
(prospector.ucsf.edu). 211 
 212 
Renal tissue samples 213 
Frozen renal tissue samples from 42 previously untreated patients who had undergone 214 
nephrectomy for sporadic ccRCC from December 2001 to December 2006 were obtained 215 
from the Leeds Multidisciplinary Research Tissue Bank (REC Ref 15/YH/0080). Tissue 216 
collection and processing was as previously described.19 Ten pairs of matched 217 
tumour/normal tissue were used for Western blot analysis. For the initial 218 
immunohistochemical studies of QPRT, frozen tissue sections from 13 tumours and 219 
matched normal kidney samples were examined. Further examination of additional 220 
proteins and across other RCC subtypes was achieved through a tissue micro-array 221 
(TMA), containing FFPE tissue cores from a further 20 patients, reviewed and selected by 222 
an experienced pathologist, from 5 normal renal cortex, 5 normal renal medulla, 11 223 
ccRCC, 6 papillary RCC and 3 chromophobe RCC samples, each arrayed in duplicate. In 224 
addition, previously generated LC-MS/MS proteomic datasets analysing 13 matched 225 
tumour/normal pairs of ccRCC tissues and 7 matched pairs of chromophobe RCC tissues 226 
were also interrogated for the purposes of this study. This dataset forms part of a larger 227 
proteogenomic study (manuscript in preparation). All included tumours were reviewed by 228 
an expert pathologist to confirm at least 70% viable tumour cells. Details of 229 






Immunocytochemistry, immunohistochemistry and Western blotting for 233 
QPRT 234 
Initial analysis of cell lines for QPRT was undertaken using affinity-purified rabbit 235 
antiserum to QPRT.23 For all other studies custom rabbit antiserum to QPRT was raised 236 
(Eurogentec, Belgium) by immunising rabbits with peptides (CDLVLLDNFKPEELHP or 237 
CVAGTRKTTPGFRLVE).  238 
Multi-well slides of 786-0 +/- VHL cell lines were fixed in acetone for 2 min, air dried, 239 
washed briefly in TBS-T, endogenous peroxidase blocked using 0.6% v/v hydrogen 240 
peroxide in methanol for 5 min and washed again. After overnight incubation at 4oC, in 241 
rabbit antiserum to QPRT diluted 1:20,000 in TBS/0.1% w/v HAS with  0.1% w/v sodium 242 
azide, slides were washed in TBS-T and labelled using the rabbit EnVision+ detection 243 
system with DAB substrate according to the manufacturer’s instructions. Slides were 244 
counterstained with Mayer’s haematoxylin and mounted using DePeX mounting medium. 245 
Negative control sections were probed with an irrelevant antibody. Immunohistochemistry 246 
on sections of frozen tumour and normal tissue (5µm OCT-embedded) was similarly 247 
performed.22  248 
Western blotting of protein lysates of cell lines or matched tumour/normal tissue was 249 
performed as previously described24 with samples separated by 10% SDS-PAGE and 250 
transfer to Hybond-C Super NC membrane in Towbin’s buffer.  After blocking with TBS-251 
T/10% w/v dried skimmed milkblots were probed with antibodies to QPRT (1:20,000), VHL 252 
(1 µg/mL) β-actin (5ng/ml; protein-loading control). After washing blots were incubated 253 
with anti-rabbit or anti mouse HRP-conjugated Envision+ reagent then washed again and 254 
exposed to film. In all cases, Western blots were normalised using densitometric scanning 255 
of parallel Coomassie blue stained gels for total protein load, given the limitations of 256 





Measurement of QUIN in renal tissue samples 259 
Sections from matched pairs of frozen tumour/normal tissue were cut into 1M HCL and 260 
stored at -80oC. QUIN levels were measured in the Schwarz lab by gas chromatography 261 
mass spectrometry (GC-MS), performed as previously described.26  262 
 263 
Effects of QPRT on Cell proliferation 264 
786+pFB and 786+QPRT cells in an exponential phase of growth were harvested and 265 
plated in 96-well plates (1 x 104 cells/ well) and cultured for 24, 48 and 72 h at 37°C with 266 
5% CO2/95% air. Viable cells were quantified using WST-1 reagent according to the 267 
manufacturer's protocol and absorbance measured at 450nm and 650nm. Wells were 268 
seeded in triplicate and three independent experiments were run. 269 
 270 
Effects of QPRT on anchorage-independent colony formation assay 271 
To investigate anchorage-independent growth of 786-0 cell lines stably transduced with 272 
constructs of interest, WT VHL (786+VHL) + shRNA scramble control, WT VHL 273 
(786+VHL) + shRNA QPRT, VHL negative + empty vector (786+pFB), VHL negative + 274 
QPRT (786+QPRT), were cultured 4 x 104 cells/well as previously described27. Viable 275 
colonies were stained with 8mM p-iodonitrotetrazolium violet and colonies with a diameter 276 
of >1mm were then counted within 10 random fields of view using an eyepiece graticule 277 
(1 cm2 area, made up of 10 x 10 mm squares) on a bright field microscope. The mean 278 
number of colonies per 10 cm2 from four independent experiments was determined. 279 
Statistical significance was assessed by Student’s T-test. The NIH3T3 cell lines containing 280 
either a control or H1047R vector were employed as negative and positive controls for the 281 





Interrogation of liquid chromatography–tandem mass spectrometry RCC 284 
proteomic datasets for kynurenine pathway changes  285 
As part of a large proteogenomic study of RCC (manuscript in preparation), LC-MS/MS 286 
proteomic datasets were created containing 13 matched tumour/normal pairs of ccRCC, 287 
and 7 matched tumour/normal pairs of chromophobe RCC following expert pathological 288 
review of selected blocks. We were able to interrogate this data for evidence of protein 289 
expression of enzymes from the kynurenine pathway.  For each sample, 30µm sections 290 
equivalent to 3cm2 surface area of tissue were lysed in excess lysis solution (250 µl of 3% 291 
SDS in 50 mM Tris-HCl, pH 7.6) and DNA sheared with brief sonication. Samples were 292 
then heated at 95°C for 10 min, centrifuged at 13,000g for 8 min, supernatant removed 293 
and protein concentration was measured by BCA assay. DTT was added to samples at a 294 
final concentration of 30 mM and samples were heated at 95oC for 5 min. 70 μg of protein 295 
was processed by the STrap protocol as previously described.28 Label-free mass 296 
spectrometry and data analysis were conducted essentially as previously described29 but 297 
using an EASY-nLC 1000 UHPLC system connected to a capillary emitter column (75µm 298 
inner diameter, packed with 3µ Pursuit C18 media) hyphenated to an LTQ-Orbitrap Velos 299 
mass spectrometer (Thermo Fisher Scientific). Data were processed against the Uniprot 300 
human protein database using Maxquant 1.3.0.5 software. Maximum false discovery rates 301 
were set to 0.01. PEP and Q-values calculate the probability of false identification for the 302 
proteins described in this study as being extremely low (p<0.001). 303 
 304 
Immunohistochemical TMA analysis of the kynurenine pathway 305 
TMA FFPE sections (4 μm) were mounted onto Plus Frost slides and dewaxing and 306 
epitope recovery was carried out by heating in a Cookworks pressure cooker for 5 min on 307 
high followed by 25 min on low temperature in Access Revelation solution. Endogenous 308 
peroxidase activity was blocked in Bloxall and 2.5% v/v normal horse serum used as a 309 




rabbit HRP-conjugated secondary antibodies followed by Impact DAB substrate for 5 min 311 
at room temperature then counterstained with Mayer's Haematoxylin for 30 seconds 312 
dehydrated, cleared in xylene and mounted in DPX. 313 
 314 
Results 315 
QPRT is down-regulated in clear cell RCC 316 
From our 2D PAGE-based comparison of whole cell lysates of 786-0 -/+VHL cells, we 317 
identified QPRT as being undetectable in -VHL cells and expressed at relatively high 318 
levels following re-introduction of WT VHL (Figure 1A and Supplementary Table 2). This 319 
was confirmed using immunocytochemistry and Western blotting of the 786-0+/-VHL cell 320 
lines (Figure 1B & C). However, this apparent VHL-dependent expression of QPRT was 321 
not observed in UMRC2 and RCC4 +/- VHL cell line pairs (Figure 1D), which all retained 322 
expression. Western blotting of frozen tissue lysates from 10 ccRCC/normal kidney 323 
matched pairs, with tumour VHL mutation status defined in all but one pair (Figure 1E) 324 
showed significant loss or down-regulation of QPRT expression in ccRCC tissues 325 
compared to their normal counterparts in 9 cases, although no relationship with VHL 326 
mutation status or mutation type was apparent. The loss of QPRT in clear cell tumours 327 
was confirmed in 12/13 patients by IHC (Figure 1F).   328 
Taken together, these results indicate that loss of QPRT is a common event in ccRCC 329 
although regulation by VHL in vitro is cell line-dependent. QPRT catalyses the conversion 330 
of quinolinic acid (QUIN), produced within the kynurenine pathway, to nicotinamide 331 
adenine dinucleotide (NAD+). The reaction catalysed by QPRT is a rate-limiting step in 332 
this pathway, therefore loss of QPRT may lead to an increase in the level of QUIN. In 333 
support of this hypothesis, we found increased levels of QUIN in ccRCC tissues relative 334 





Knockdown of QPRT in 786-0 cells increases cellular anchorage-337 
independent growth in vitro 338 
786-0 cells (VHL-negative) transfected with a QPRT expression construct (786+QPRT) 339 
showed stable overexpression of QPRT (Figure 2A). Conversely, transfection of 340 
786+VHL (VHL-expressing) cells with an shRNA construct targeting QPRT 341 
(786+VHL+shQPRT) cells significantly reduced QPRT protein expression (Figure 2B). 342 
QPRT expression in cells transfected with empty vector was unaffected. 343 
Using this model, no significant effect of QPRT loss/gain on cell proliferation was observed 344 
(Figure 2C and D). However, in a  soft-agar colony formation assay (Figures 2E and F),  345 
whereas all 786-0 cells irrespective of whether +/-VHL formed small colonies (diameter of 346 
>1mm),  786+QPRT cells showed significantly reduced  colony formation as compared to 347 
786+pRC controls (p=0.017) (Figure 2E) and 786+VHL+shQPRT cells showed a 348 
significantly (p=0.001) higher frequency of colonies relative to both the 349 
786+VHL+scramble and 786+VHL cells (Figure 2F). Colony size was also affected by 350 
QPRT expression status. Amongst QPRT-positive cell lines, only 10% of colonies were 351 
estimated to exceed 3mm in diameter, versus approximately 50% of colonies amongst 352 
QPRT-negative cells lines. 353 
 354 
Dysregulation of the kynurenine pathway occurs at multiple points and is 355 
common to both clear cell and chromophobe RCC 356 
Interrogation of existing LC-MS/MS proteomic datasets across other proteins within the 357 
kynurenine pathway  confirmed the decrease in QPRT in ccRCC, identifying a total of 6 358 
unique peptides (Supplementary Table 3), which together represent 18.5% of the entire 359 
protein sequence. A consistent and significant decrease in the number of QPRT peptides 360 
identified, and in normalised (LFQ) peptide intensities (representing relative 361 




similar findings were observed for other enzymes of the kynurenine pathway, namely 3-363 
hydroxyanthranilite 3,4-dioxygenase (HAAO), and kynurenine 3-monoxygenase (KMO) 364 
(Figure 3A). Conversely, nicotinamide phosphoribosyl transferase (NAMPT; which is a 365 
key enzyme in the production of NAD+ via the alternative salvage pathway), was 366 
upregulated in most tumour samples (Figure 3A). IDO was not detected in any samples. 367 
In the dataset for the seven matched pairs of chromophobe RCC versus normal kidney, 368 
very similar results as for ccRCC were obtained, with expression of QPRT, KMO and 369 
HAAO being below the level of detection in tumours (with one exception). NAMPT again 370 
showed increased expression in the tumours and was undetectable in all but one of the 371 
normal kidney tissue samples (Figure 3B).  372 
Four other kynurenine pathway proteins were also detected in our proteomic datasets. 373 
Kynurenine formamidase (AFMID), kynureninase (KYNU) and kynurenine 374 
aminotransferase 1 and 3 (KYAT1, KYAT3) were all observed in the chromophobe 375 
dataset, while AFMID and KYAT3 were also detected in the ccRCC data. All four proteins 376 
showed a pattern of presence in normal tissue, and loss in tumour tissue. However, the 377 
number of peptides detected in each sample was low (1-3), and the intensities were near 378 
to the limit of detection. For this reason, while these data suggest a pattern of altered 379 
expression for these four proteins, it should not yet be considered as conclusive. 380 
In addition, dysregulation of expression of QPRT, KMO, HAAO and NAMPT, largely 381 
mirroring changes observed at the protein level,  was confirmed transcriptomically through 382 
examination of our previously generated RNA seq data, amongst 45 matched tumour 383 
(ccRCC) / normal tissue pairs (Figure 4).30 Equivalent data for papillary and chromophobe 384 
RCCs are shown in Supplementary Figures 1 and 2, respectively, based on data from 385 
the TCGA Research Network.31  386 
The observed changes, and how these impact on the kynurenine pathway are 387 





Immunohistochemical TMA analysis of the kynurenine pathway by TMA 390 
In normal renal cortex, weak to moderate granular staining of proximal tubules 391 
(predominantly cytoplasmic) was observed for IDO1 and moderate/strong expression 392 
of KYNU, QPRT and KMO with absent to moderate staining for NAMPT.  In the case of 393 
KMO, staining was noticeably localised to basolateral aspect of the tubules.  Glomerular 394 
reactivity was also seen for NAMPT and KYNU.  In the medulla, tubules were largely 395 
negative although two cases showed weak expression of IDO1, NAMPT and QPRT 396 
although one of these showed distinct populations of tubules with moderate QPRT 397 
staining (Figure 6).  398 
In clear cell RCC cases, expression of IDO1, KYNU, QPRT and KMO was greatly reduced 399 
compared with normal kidney cortex and in some cases was absent (Figure 6, 400 
Supplementary Table 4).  IDO1 was not detected in tumour cells but only in occasional 401 
inflammatory cells or in endothelial cells and KMO1 was also seen in some endothelial 402 
cells..  For QPRT, 5 cases were completely negative, 4 cases showed only focal positivity 403 
and 2 weak to moderate staining.  Conversely, NAMPT expression was absent from clear 404 
cell tumour cells in 2 cases but positive in 5 (from weak to strong) with focal positivity seen 405 
in a further 4 cases.  Positive staining was also seen with occasional inflammatory cells 406 
and endothelial cells. Of note the strongest staining for any of the enzymes in the ccRCC 407 
cases was in the rhabdoid cells in case 4728. A similar pattern of generally reduced 408 
staining compared with normal kidney was also seen with papillary and chromophobe 409 
cases and generally weak to moderate NAMPT. The findings were consistent with our 410 
mass spectrometry results and demonstrate that disruption of the kynurenine pathway is 411 






This study provides the first comprehensive demonstration of a wide, and coordinate 415 
dysregulation of the kynurenine pathway in RCC and that this is a common, unifying event, 416 
highlighting its importance in the pathogenesis of these cancers and potentially providing 417 
insights of relevance to therapeutic targeting. 418 
The kynurenine pathway is the main route for degradation of the essential amino acid 419 
tryptophan and de novo synthesis of  nicotinamide adenine dinucleotide (NAD+), 420 
generating numerous other active intermediate metabolites including kynurenine (KYN), 421 
kynurenic acid, anthranilic acid, picolinic acid and quinolinic acid (QUIN). Dysregulation of 422 
the pathway was initially highlighted in neuropsychiatric disorders but has now been 423 
implicated more widely10 and increasingly in tumourigenesis and immune evasion. 424 
Although in the liver, where the majority of tryptophan degradation occurs, constitutively 425 
expressed TDO2 is the initial rate-limiting enzyme in the pathway, in most other tissues 426 
IDO1 is the first and rate-limiting enzyme. Inducible by inflammatory cytokines, IDO/IDO1 427 
has been reported to be expressed in many cancers and hypothesised to play a role in 428 
tryptophan degradation and  accumulation of active metabolites in the kynurenine 429 
pathway, both of which result in T-cell/immune suppression leading to the idea of IDO1 430 
inhibitors as useful anti-cancer therapeutics  to overcome immune resistance, for example 431 
in combination with vaccine strategies.13,32 However, IDO1 expression is highly dependent 432 
on tumour type and many cancers including renal, melanoma and thyroid have absent or 433 
low expression of IDO1 in tumour cells in most cases.32 This has been confirmed 434 
subsequently with the demonstration of IDO1 expression in endothelial cells and 435 
macrophages in RCC tissues33,34 and a recent extensive study across many cancers 436 
where although 80% of renal carcinomas were positive, IDO1 was absent from tumour 437 
cells and present predominantly in endothelial cells or in some lymphocyte-rich stroma.35 438 
This in agreement with our IHC results and with the relatively low expression being 439 




We initially observed that in a VHL +/- cell line pair, expression of QPRT increased 441 
following the introduction of VHL. QPRT is the final enzyme in the kynurenine pathway, 442 
converting QUIN to NAD+. However, it is apparent that this is not mainly VHL-dependent 443 
and may be an indirect effect, since this was not seen in other VHL-transfectant cell line 444 
models and changes in QPRT expression were subsequently shown to occur in ccRCC 445 
independent of VHL mutation status and in chromophobe and papillary RCC tissues 446 
where VHL is not involved. We  subsequently learnt that the 786-pRC cell line we 447 
employed also contains a p53 mutation (personal communication from WGK to RC), 448 
although we do not believe this to be implicated either, since p53 mutations are rarely 449 
seen in RCC.3 The underlying biology leading to such dysregulation, and whether 450 
common or divergent mechanisms are responsible, remains uncertain, but its consistency 451 
across more than one type of RCC suggests it is a key and potentially early event.  452 
 As predicted, we found that that loss of QPRT was associated with  increased QUIN in 453 
tumour tissue, and metabolomic studies of urine and tissue samples from RCC patients 454 
reported higher concentrations of quinolinate compared with healthy controls 36 or normal 455 
tissue.37  QUIN has been reported to activate b-Catenin and increase proliferation in colon 456 
cancer cell lines38 and in RCC cell lines, variable effects of quinolinate on cell viability or 457 
proliferation have been reported although very different quinolinate concentrations have 458 
been used across studies.36,39 We did not observe increased cell proliferation in our in 459 
vitro QPRT knock-down model. However, we did see a pronounced increase in 460 
anchorage-independent growth in response to loss of QPRT. It is possible that this is 461 
mediated by QUIN accumulation and exerting this effect through a potential autocrine loop 462 
involving N-methyl-D-aspartate receptors (NMDAR), since this receptor-ligand binding is 463 
important for its role in neurological disease40 and expression of NMDAR subunits has 464 
been demonstrated in the normal kidney cortex and medulla and across multiple cancer 465 
types, with receptor blockade reducing cancer cell proliferation and invasiveness in 466 




example, treatment with QUIN induced the selective apoptosis in vitro of murine 468 
thymocytes and of Th1 but not Th2 cells and mice treated with QUIN had significantly 469 
reduced levels of immature thymocytes in the thymus.42 In a microenvironment deficient 470 
in tryptophan, QUIN was found to inhibit proliferation of both lymphocytes and NK cells.43 471 
Interestingly, accumulation of QUIN has been reported to occur in human gliomas but 472 
accompanied by increased QPRT expression and supporting NAD generation through 473 
this pathway rather than the NAMPT-mediated pathway.44 QPRT was shown to be 474 
induced by oxidative stress, temozolomide and irradiation and to be associated with 475 
poorer prognosis in recurrent tumours after radiochemotherapy, potentially through 476 
increasing resistance. These results suggest that targeting QPRT itself may be a potential 477 
therapeutic option and indeed data from a cell line model have implicated upregulation of 478 
QPRT as conferring resistance to NAMPT inhibitors.45    479 
Examination of a parallel existing LC-MS/MS proteomic dataset generated by our group 480 
as part of an ongoing proteogenomic study in RCC, not only confirmed loss of QPRT in 481 
RCC, but also showed loss of five other enzymes in the kynurenine pathway, namely 482 
HAAO, KMO, kynurenine formamidase, and KYAT1 and 2. Remarkably little is known 483 
about these enzymes in cancer although upregulation of KMO has been described in 484 
hepatocellular carcinoma.46 This may be due at least in part to the lack of availability of 485 
good antibodies, at least until recently, which is why we generated our own QPRT 486 
antibody. Critically, one can expect that loss of KMO, alongside an increase in IDO 487 
expression, will lead to the accumulation in tumour tissue of kynurenine. In metabolomic 488 
studies of mouse RCC xenografts and human RCC tumours, significantly lower 489 
tryptophan and higher kynurenine levels and higher quinolinate and kynurenine levels, 490 
respectively, were seen in tumours compared with controls.37,47 A metabolomic study 491 
involving ccRCC along with chromophobe and papillary tissue samples also identified 492 
elevated kynurenine compared with controls, but in ccRCC cases only.48 The immune 493 




T-cell and NK  cell proliferation and promote immune suppression via the aryl hydrocarbon 495 
receptor (AhR).32,43,49 Furthermore, it can promote cancer cell survival and motility38,49. 3-496 
hydroxyanthranilic acid (3-HAA), the substrate for HAAO, has also been shown to have 497 
multiple roles in promoting tumour immune evasion, by promoting apoptosis of Th1 and 498 
NK cells, promoting differentiation of Treg cells and inhibiting T-cell proliferation.10,42 499 
This novel observation, that multiple enzymes in the kynurenine pathway downstream of 500 
IDO are all downregulated, and in a manner likely to promote tumourigenesis and immune 501 
evasion, is striking. The loss of QPRT, and hence the blockade of de novo biosynthesis 502 
of NAD+ may initially seem at odds with the requirement of cells, and especially cancer 503 
cells, for this molecule.50 However, NAD+ may also be made from nicotinamide via the 504 
salvage pathway of which the enzyme NAMPT is a key component, and this pathway is 505 
often preferred in cancer cells.51 Consistent with this, we observed up-regulation of 506 
NAMPT occurring as a common event in RCC, confirming a recent IHC study.52 As such, 507 
NAMPT forms an attractive therapeutic target and it is of note that KPT-9274, a 508 
NAMPT/PAK4 inhibitor, has recently been reported to have activity against renal cancer 509 
xenografts.53 510 
The kynurenine pathway forms a particularly attractive target for therapy, since it seems 511 
to regulate tolerance to non-self-antigens, rather than to self-antigens,11,12 thus reducing 512 
the risk of immune-related adverse events often seen with immune-checkpoint inhibition. 513 
Whether inhibition of IDO1 alone is sufficient to overcome pathway dysregulation is 514 
uncertain, as exemplified by the recent negative results seen with epacadostat in patients 515 
with melanoma.14 Indeed, a planned phase 3 trial of this agent in combination with 516 
pembrolizumab in patients with RCC has been halted based on these findings. Whilst 517 
combined IDO1/TDO inhibitors are currently in early phase trials (NCT03208959), our 518 
results suggest that, in RCC at least, the kynurenine pathway is much more widely 519 





Our study has its limitations and a number of questions remain unanswered that would 522 
need to be explored in future studies. Whether the phenotypic consequences of loss or 523 
gain of QPRT extend beyond effects on colony formation, for example, and whether such 524 
changes are consistently observed across RCC cell lines, remains uncertain. 525 
Furthermore, since the 786-0 cell line is known to contain a PTEN mutation (although 526 
rarely observed in clear cell RCC tissues),30 it would be of interest to examine how 527 
deficiency of PTEN and/or dysregulation of the PI3K/AKT/mTOR signalling pathway 528 
impacts QPRT expression. We have also not examined how dysregulation of the 529 
kynurenine pathway in RCC correlates with patient outcomes. 530 
 531 
In conclusion, we have demonstrated a widespread and apparently co-ordinated 532 
dysregulation of the kynurenine pathway in RCC. These findings have implications for 533 
current strategies aimed at therapeutically targeting this critical pathway and highlight the 534 
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Figure Legends 750 
Figure 1. QPRT expression is lost in clear cell RCC (ccRCC) A). 2D PAGE comparing 751 
786-0 cell lines, +/- wild-type VHL. The protein spot identified as QPRT is arrowed. B). 752 
Immunocytochemistry of 786-0 +/- cell lines for QPRT. C,D,E). Western blotting for QPRT 753 
in C). 786-0 +/- VHL cell lines; D. 786-0, RCC4 and UMRC2 cell lines +/- wild-type VHL; 754 
E. Paired normal/ccRCC tumour tissue lysates. VHL mutation status is indicated (one 755 
tumour was of unknown VHL status: FS = frame shift, N = nonsense, M = mis-sense). 756 
Promoter methylation status was analysed in one of the two tumours containing no VHL 757 
mutation and confirmed as negative F. Immunohistochemistry for QPRT of a 758 
representative example of normal and ccRCC tissue (40x magnification). G. quinolinic 759 
acid content of paired normal/ccRCC tumour tissue samples determined by mass 760 
spectrometry.  761 
Figure 2. Loss of QPRT expression increases anchorage independent growth. A). 762 
Western blot showing QPRT expression in control and QPRT-transfected VHL negative 763 
786-0 cell lines. B). QPRT expression in control and anti-QPRT shRNA transfected, VHL-764 
expressing 786-0 cell lines. A single band at the expected molecular weight was observed. 765 
C). and D). Relative cell number of 786-0 cell lines plus or minus QPRT, as measured 766 
using WST1 assay. E) and F). Impact of QPRT transfection or knockdown on relative 767 
colony number in soft agar colony formation assay and representative images. Colony 768 
number per 10 cm2 are provided as a mean of the sum over four independent experiments 769 
and then standardised as a percentage to either 786+pRC or 786+VHL controls. 770 
Significant differences are indicated (*; 786+QPRT vs 786+pFB, p=0.017, 771 
786+VHL+shQPRT vs either control, p=0.001) 772 
Figure 3. Multiple proteins in the kynurenine pathway are dysregulated in RCC.  773 
Mass spectrometric relative concentrations (LFQ intensity) of proteins in the kynurenine 774 
pathway for paired normal kidney/tumour tissue samples (black and grey bars 775 
respectively) for A). ccRCC and B) chromophobe RCC. Numbers along x-axis refer to 776 
assigned tissue sample number. Differences between groups by Wilcoxon matched-pairs 777 
sign rank test: Clear cell RCC: QPRT (p<0.001), KMO (p<0.001), HAAO (p=0.01) and 778 
NAMPT (p<0.01); Chromophobe RCC: QPRT (p<0.016), KMO (p<0.016), HAAO 779 
(p<0.016), and NAMPT (p<0.016) 780 
 781 
Figure 4. Gene expression of QPRT, KMO, HAAO and NAMPT is similarly 782 
dysregulated in clear cell RCC. Data derived from transcriptomic (RNA-seq) analysis of 783 
45 paired normal kidney/tumour tissue samples 30.  Numbers along x-axis refer to 784 
assigned tissue sample number. FPKM - fragments per kilo bases of exons per million 785 
mapped reads. Differences between groups by Wilcoxon matched-pairs sign rank test: 786 
QPRT (p<0.001), KMO (p=0.004), HAAO (p=0.001) and NAMPT (p<0.001).  787 
 788 
Figure 5. Alterations to the kynurenine pathway in RCC. The various enzymes and 789 
intermediates generated through this de novo synthesis of NAD+ from tryptophan are 790 
shown together with the salvage pathway route for generation of NAD+ from nicotinamide, 791 
catalyzed by NAMPT. Enzymes for which we have strong evidence of down-regulation in 792 
RCC tissues are marked with a solid grey arrow. Enzymes or substrates observed to be 793 
up-regulated are marked with a hatched arrow. Substrates with evidence to suggest they 794 
may be up-regulated are marked by an open grey arrow. 795 
Figure 6.   Immunohistochemical analysis of kynurenine pathway enzymes. 796 




KYNU, QPRT and NAMPT in  the normal renal cortex and medulla and different 798 
subtypes of RCC using a TMA. 799 
